Employers Are Overpaying Up to 41% on GLP-1s.
We Can Fix That.
GLP-1 medications for weight loss are skyrocketing in popularity, and many employers are unaware of the impact this demand has on their bottom line.
Do you have a clear view of your GLP-1 utilization and spending? If not, you’re most likely overspending without realizing it.
If you don’t have a solution to address these skyrocketing costs as well as the growing challenges of obesity – now is the time to act!
A review of PBM claims data shows a sharp increase in GLP-1 utilization and spend from 2022 to 2024. This trend will continue.
Introducing Ivím at Work:
A game changer for employee health and wellness
With Ivím at Work, you can offer a robust
medical weight loss benefit at a
sustainable cost.
medical weight loss benefit at a
sustainable cost.
- Up to 80% savings on GLP-1 drug therapies
- The ability to design a custom solution that fits unique goals and budgets
- Personalized clinical care management to support sustained weight loss
- Real-time visibility into plan performance for greater control
Employers Achieve
- Up to 80% savings on GLP-1 therapies1
- ~$8,000 savings per participating member per year1
Employees Achieve
- 17% average weight loss
over 12 months2 - ~1-1.7 average percentage point reduction in A1C3
Let’s discuss how Ivím at Work can be the game-changer your company needs.
Ivím at Work with Xevant Personalized Care. Accessible Solutions. Proven Results.
